Cetera Investment Advisers
NTLA icon

Cetera Investment Advisers’s Intellia Therapeutics NTLA Stock Holding History

Cetera Investment Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
66,942
+13,149
+24% +$184K ﹤0.01% 2940
2026
Q1 		$690K Buy
53,793
+3,192
+6% +$40.7K ﹤0.01% 3229
2025
Q4 		$455K Buy
50,601
+13,849
+38% +$191K ﹤0.01% 3517
2025
Q3 		$635K Buy
36,752
+3,220
+10% +$39.7K ﹤0.01% 3188
2025
Q2 		$315K Buy
33,532
+10,785
+47% +$88.6K ﹤0.01% 3354
2025
Q1 		$162K Buy
22,747
+9,599
+73% +$97K ﹤0.01% 3662
2024
Q4 		$153K Sell
13,148
-4,788
-27% -$74.7K ﹤0.01% 3496
2024
Q3 		$369K Sell
17,936
-4,731
-21% -$109K ﹤0.01% 2895
2024
Q2 		$507K Sell
22,667
-26,286
-54% -$626K ﹤0.01% 2580
2024
Q1 		$1.35M Buy
+48,953
New +$1.36M ﹤0.01% 1843
2022
Q2 		– Sell
-2,915
Closed -$212K – 1913
2022
Q1 		$212K Sell
2,915
-141
-5% -$11.9K ﹤0.01% 1675
2021
Q4 		$361K Buy
3,056
+25
+0.8% +$3.13K 0.01% 1382
2021
Q3 		$407K Sell
3,031
-256
-8% -$38.8K 0.01% 1257
2021
Q2 		$532K Buy
+3,287
New +$256K 0.01% 1092

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Cetera Investment Advisers's NTLA Position: Q2 2026 in Review

Cetera Investment Advisers increased its Intellia Therapeutics (NTLA) stake by 24% in Q2 2026, buying an estimated $184K and bringing the position to 66,942 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2940.

Cetera Investment Advisers first reported a position in NTLA in Q2 2021 and has held it in 14 quarters since. The position peaked at $1.35M in Q1 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Cetera Investment Advisers held 66,942 shares of Intellia Therapeutics worth $1.13M as of Q2 2026.
  • Cetera Investment Advisers bought 13,149 Intellia Therapeutics shares in Q2 2026, an estimated $184K.
  • Intellia Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #2940 holding.
  • Cetera Investment Advisers first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • Cetera Investment Advisers's Intellia Therapeutics position peaked at $1.35M in Q1 2024.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.